Your browser is no longer supported. Please, upgrade your browser.
Pharming Group N.V.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand63.88M Perf Week-1.55%
Market Cap504.99M Forward P/E- EPS next Y- Insider Trans- Shs Float63.04M Perf Month-15.64%
Income- PEG- EPS next Q- Inst Own0.28% Short Float0.01% Perf Quarter-21.23%
Sales174.40M P/S2.90 EPS this Y- Inst Trans- Short Ratio0.81 Perf Half Y-37.01%
Book/sh- P/B- EPS next Y- ROA- Target Price7.35 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.58 - 21.99 Perf YTD-47.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low4.29% ATR0.34
Employees262 Current Ratio- Sales Q/Q5.00% Oper. Margin- RSI (14)36.54 Volatility2.32% 2.64%
OptionableNo Debt/Eq- EPS Q/Q-50.10% Profit Margin- Rel Volume1.10 Prev Close7.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume9.81K Price7.91
Recom- SMA20-8.46% SMA50-13.51% SMA200-31.98% Volume10,782 Change4.29%
Nov-02-21 06:54PM  
Oct-28-21 03:05PM  
Oct-22-21 01:00AM  
Sep-14-21 01:00AM  
Aug-05-21 01:00AM  
Jul-20-21 01:00AM  
Jul-01-21 10:35AM  
Jun-23-21 01:00AM  
Jun-18-21 01:00AM  
Jun-04-21 01:00AM  
Jun-01-21 01:00AM  
May-19-21 04:31PM  
May-17-21 01:00AM  
May-13-21 01:00AM  
Apr-22-21 01:00AM  
Apr-07-21 04:00PM  
Apr-06-21 05:30PM  
Mar-23-21 02:00AM  
Mar-16-21 08:10AM  
Mar-11-21 01:00AM  
Mar-04-21 01:00AM  
Mar-02-21 01:00AM  
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.